Third Time's the Charm: FDA Approves Replimune's Tudriqev (RP1) for Advanced Melanoma
On Aug 6, 2026, the FDA granted accelerated approval to Replimune’s Tudriqev (RP1) with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy. Based on IGNYTE (n=140), FDA efficacy-evaluable ORR was 24.2% with median DoR 14.1 months. Replimune set a $450,000 list price per course; approval is conditional on Phase 3 IGNYTE-3.
How this was made
The 30-second read
Why it matters
The FDA’s accelerated approval, supported by an advisory committee vote and a defined post-anti-PD-1 indication, creates a new revenue pathway while making confirmatory IGNYTE-3 the key overhang.
Market read
This is a primary regulatory catalyst with commercialization details and a clear confirmatory trial risk, making it tradable for both momentum and risk management.
What to watch
Commercial execution risk is high: $450k list price, payer access, and safety labeling (herpetic infection and exposure warnings) could limit uptake despite efficacy signals.
Background
Replimune’s RP1 (Tudriqev) faced two FDA Complete Response Letters after a single-arm submission, including criticism of interpretability due to heterogeneous enrollment.
Ticker impact
FDA granted accelerated approval to Replimune’s Tudriqev (RP1) plus nivolumab for unresectable advanced cutaneous melanoma after anti-PD-1 progression.
Near-term upside bias on commercialization expectations, with volatility tied to IGNYTE-3 readout risk.
The article reports a specific FDA accelerated approval, a PDUFA date, advisory committee vote, and first launch pricing, which are direct catalysts for valuation and trading positioning.
Market effects
Oncolytic virus and post-anti-PD-1 melanoma franchises may see improved sentiment after an FDA reversal and advisory committee support.
US biotech sentiment positive, with potential spillover to other immuno-oncology and gene therapy names.
US regulatory precedent may influence global development and investor appetite for oncolytic immunotherapies.
Counterpoint
Accelerated approval can de-rate if IGNYTE-3 fails to confirm benefit, so the stock may already price in optimism ahead of 2030 data.
Key entities
- companyReplimune
NASDAQ-listed biotech receiving FDA accelerated approval for Tudriqev (RP1) plus nivolumab in advanced cutaneous melanoma.
- drugTudriqev (RP1)
Oncolytic immunotherapy injected into tumors, used with nivolumab for patients progressed on anti-PD-1 therapy.
- regulatorFDA
Granted accelerated approval and previously issued two CRLs, with leadership changes cited as part of the turnaround.
- clinical_trialIGNYTE-3
Phase 3 confirmatory trial with overall survival as the primary endpoint, data expected in 2030.
